Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

October 17, 2022

Study Completion Date

December 31, 2025

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Sunvozertinib

Daily dose of Sunvozertinib

Trial Locations (33)

Unknown

Beijing Cancer Hospital, Beijing

Beijing Chest Hospital,Capital Medical University, Beijing

Peking Union Medical College Hospital, Beijing

Peking University Third Hospital, Beijing

Jilin Cancer Hospital, Changchun

Hunan Cancer Hospital(The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha

West China Hospital of Sichuan University, Chengdu

Army Medical Center of PLA, Chongqing

Chongqing University Cancer Hospital(Chongqing Cancer Hospital), Chongqing

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

Hainan General Hospital, Haikou

The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

Zhejiang Cancer Hospital (Cancer Hospital of the University of Chinese Academy of Sciences), Hangzhou

Harbin Medical University Cancer Hospital, Harbin

The Second Hospital of Anhui Medical University, Hefei

The Affiliated Hospital of Inner Mongolia Medical University, Hohhot

Jinan Central Hospital (Central Hospital Affiliated to Shandong First Medical University), Jinan

Yunnan Cancer Hospital, Kunming

The First Affiliated Hospital of Nanchang University, Nanchang

The Second Affiliated Hospital of Nanchang University, Nanchang

Fudan University Shanghai Cancer Center, Shanghai

The First Hospital of China Medical University, Shenyang

The Fourth Hospital of Hebei Medical University, Shijiazhuang

The First Affiliated Hospital of Soochow University, Suzhou

Shanxi Provincial Cancer Hospital, Taiyuan

Tianjin Medical University Cancer Institute & Hospital, Tianjin

The Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi

Hubei Cancer Hospital, Wuhan

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

Affiliated Cancer Hospital of Zhengzhou University(Henan Cancer Hospital), Zhengzhou

Sponsors
All Listed Sponsors
lead

Dizal Pharmaceuticals

INDUSTRY

NCT05712902 - Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) | Biotech Hunter | Biotech Hunter